Abstract
Background
Methods
Results
Conclusions
Keywords
Introduction
- Hartley R.A.
- Barker B.L.
- Newby C.
- et al.
Materials and methods
Study subject data
Computed tomography image acquisition and analysis

Visual analysis by radiologists
Clustering and statistical analyses
Results
Characteristic lung imaging metrics of 4 QCT-based clusters


Clinical characteristics of 4 QCT-based clusters
Clinical characteristics | Cluster 1 (N = 7) | Cluster 2 (N = 33) | Cluster 3 (N = 16) | Cluster 4 (N = 5) | P value |
---|---|---|---|---|---|
Asthma severity (Severe) | 1 (14.2%) | 14 (42.4%) | 13 (81.3%) | 5 (100%) | <0.005 |
Age (y) | 74.0 [64.5; 77.0] | 62.0 [53.0; 68.0] | 69.0 [62.5; 74.5] | 67.0 [63.0; 68.0] | <0.05 |
Onset age of asthma (y) | 59.0 [54.0; 65.0] | 46.0 [36.0; 55.0] | 54.0 [44.3; 62.0] | 54.0 [40.0; 59.0] | <0.05 |
Disease duration (y) | 11.0 [09.0; 12.5] | 12.0 [09.0; 19.0] | 14.0 [09.8; 17.0] | 17.0 [14.0; 23.0] | 0.463 |
Sex (female) | 7 (100%) | 26 (78.8%) | 7 (43.8%) | 0 (0%) | <0.001, |
Smoking status (Never/Former/Current) | 7/0/0(100/0/0%) | 26/5/2(79/15/6%) | 11/4/1(69/25/6%) | 0/5/0(0/100/0%) | <0.005 |
Smoking history (pack-years) | 0 | 4.9 ± 15.0 | 7.5 ± 11.7 | 35 ± 23.0 | <0.001,, |
BMI (kg/m2) | 23.7 ± 2.5 | 25.0 ± 3.2 | 24.0 ± 1.7 | 23.0 ± 1.4 | 0.3 |
Sinusitis | 4 (56.8%) | 19 (57.6%) | 12 (75%) | 3 (60%) | 0.682 |
Nasal polyp | 0 (0%) | 4 (12.1%) | 4 (25%) | 0 (0%) | 0.281 |
Atopy | 1 (14.2%) | 10 (30.3%) | 6 (37.5%) | 1 (20%) | 0.683 |
Total IgE (IU/ml) | 30.0 [4.0; 45.0] | 88.0 [37.0; 192.0] | 441.0 [69.5; 1099.5] | 31.0 [30.0; 40.0] | <0.05 |
Sputum eosinophil (%) | 4.0 [3.7; 4.3] | 4.1 [3.0; 8.4] | 6.3 [3.0; 14.7] | 10.0 [9.2; 11.5] | 0.607 |
Sputum neutrophil (%) | 11.0 [5.8; 17.3] | 1.3 [0.8; 2.8] | 1.0 [0.4; 3.0] | 1.0 [0.7; 1.3] | 0.858 |
FeNO (ppb) | 9.5 (7.8) | 27.8 (16.0) | 24.5 (14.0) | 20.3 (15.0) | 0.353 |
PC20 (mg/ml, at diagnosis) | 21.0 [7.4; 22.0] | 6.7 [3.5; 15.2] | 3.4 [2.0; 7.6] | 0.6 [0.3; 1.1] | <0.01, |
Pre-BD FVC (%pred) | 93.0 ± 22.5 | 78.2 ± 16.0 | 67.9 ± 22.6 | 75.4 ± 15.3 | 0.152 |
Pre-BD FEV1 (%pred) | 105 ± 24.8 | 80.5 ± 17.3 | 67.3 ± 20.8 | 52.6 ± 12.5 | <0.001,, |
Pre-BD FEV1/FVC (%) | 91.0 ± 3.7 | 84.7 ± 7.6 | 74.1 ± 11.8 | 57.2 ± 5.8 | <0.001,,, |
Post-BD FVC (%pred) | 94.3 ± 23.7 | 82.2 ± 14.5 | 71.8 ± 15.2 | 85.6 ± 18.7 | 0.072 |
Post-BD FEV1 (%pred) | 109 ± 25.6 | 86.1 ± 17.6 | 71.4 ± 19.9 | 57.4 ± 11.8 | <0.001,,, |
Post-BD FEV1/FVC (%) | 93.6 ± 4.7 | 85.3 ± 6.8 | 75.6 ± 12.6 | 55.2 ± 4.3 | <0.001, ,,,, |
Fixed obstruction | 0 (0%) | 1 (3%) | 4 (25%) | 4 (80%) | <0.001 |
No. of controller medications | 1.3 ± 0.8 | 1.4 ± 0.9 | 2.3 ± 1.2 | 2.6 ± 1.5 | <0.05 |
Maintenance of OCS (%) | 2 (28.6%) | 9 (27.3%) | 10 (62.5%) | 4 (80%) | <0.05 |
No. of acute exacerbations (per year, 2012–2017) | 0.2 [0.1; 0.4] | 0.0 [0.0; 0.5] | 0.4 [0.2; 0.8] | 1.0 [0.3; 1.5] | <0.05 |

Comparison of grouping by clustering-based groups vs. radiologists
CT-basedmetrics | NN type (N = 38) | LA type (N = 18) | SA type (N = 5) | P value | Healthy subjects | |
---|---|---|---|---|---|---|
WT | Trachea | 1.014 ± 0.082 | 1.010 ± 0.077 | 1.040 ± 0.043 | 0.685 | 0.970 ± 0.093 |
RMB | 0.936 ± 0.150 | 0.919 ± 0.156 | 1.013 ± 0.039 | 0.662 | 0.857 ± 0.143 | |
Bronint | 0.688 ± 0.062 | 0.683 ± 0.045 | 0.677 ± 0.039 | 0.966 | 0.671 ± 0.061 | |
LMB | 0.719 ± 0.099 | 0.730 ± 0.109 | 0.822 ± 0.164 | 0.304 | 0.724 ± 0.105 | |
TriLLB | 0.667 ± 0.052 | 0.681 ± 0.082 | 0.640 ± 0.036 | 0.338 | 0.632 ± 0.041 | |
sRUL | 0.601 ± 0.044 | 0.590 ± 0.039 | 0.601 ± 0.019 | 0.755 | 0.573 ± 0.037 | |
sRML | 0.575 ± 0.051 | 0.569 ± 0.045 | 0.550 ± 0.052 | 0.763 | 0.551 ± 0.038 | |
sRLL | 0.583 ± 0.045 | 0.559 ± 0.032 | 0.578 ± 0.031 | 0.152 | 0.552 ± 0.041 | |
sLUL | 0.558 ± 0.029 | 0.537 ± 0.032 | 0.540 ± 0.021 | <0.05 | 0.526 ± 0.039 | |
sLLL | 0.602 ± 0.042 | 0.584 ± 0.040 | 0.573 ± 0.018 | 0.175 | 0.572 ± 0.039 | |
Total | 0.584 ± 0.037 | 0.568 ± 0.030 | 0.569 ± 0.016 | 0.295 | 0.555 ± 0.032 | |
Dh | Trachea | 0.987 ± 0.100 | 1.021 ± 0.068 | 0.944 ± 0.061 | 0.092 | 0.916 ± 0.089 |
RMB | 0.825 ± 0.079 | 0.795 ± 0.050 | 0.752 ± 0.055 | 0.055 | 0.766 ± 0.087 | |
Bronint | 0.607 ± 0.052 | 0.618 ± 0.053 | 0.613 ± 0.056 | 0.885 | 0.579 ± 0.056 | |
LMB | 0.668 ± 0.073 | 0.653 ± 0.052 | 0.655 ± 0.032 | 0.834 | 0.615 ± 0.065 | |
TriLLB | 0.486 ± 0.059 | 0.447 ± 0.076 | 0.411 ± 0.062 | <0.05 | 0.441 ± 0.058 | |
sRUL | 0.313 ± 0.043 | 0.278 ± 0.044 | 0.302 ± 0.062 | <0.05 | 0.282 ± 0.038 | |
sRML | 0.273 ± 0.041 | 0.248 ± 0.042 | 0.233 ± 0.052 | 0.127 | 0.257 ± 0.039 | |
sRLL | 0.288 ± 0.047 | 0.249 ± 0.047 | 0.260 ± 0.067 | <0.01 | 0.267 ± 0.044 | |
sLUL | 0.242 ± 0.029 | 0.216 ± 0.032 | 0.224 ± 0.038 | <0.05 | 0.232 ± 0.030 | |
sLLL | 0.325 ± 0.045 | 0.268 ± 0.041 | 0.259 ± 0.038 | <0.001 | 0.290 ± 0.040 | |
Total | 0.288 ± 0.033 | 0.252 ± 0.032 | 0.256 ± 0.048 | <0.005 | 0.266 ± 0.031 | |
Emph% | RUL | 1.0 ± 1.0 | 1.4 ± 1.9 | 17.1 ± 10.3 | <0.001, | 0.7 ± 1.4 |
RML | 1.8 ± 1.9 | 2.6 ± 2.1 | 5.8 ± 1.4 | <0.001, | 1.9 ± 3.0 | |
RLL | 0.8 ± 1.3 | 1.2 ± 1.0 | 11.0 ± 7.3 | <0.001,, | 0.8 ± 1.3 | |
LUL | 1.2 ± 1.4 | 2.4 ± 2.7 | 17.0 ± 5.5 | <0.001,, | 1.1 ± 2.0 | |
LLL | 1.0 ± 1.2 | 2.3 ± 2.6 | 11.6 ± 4.4 | <0.001, | 1.0 ± 1.4 | |
Total | 1.1 ± 1.2 | 1.9 ± 1.9 | 13.0 ± 4.8 | <0.001, | 1.0 ± 1.6 | |
fSAD% | RUL | 9.9 ± 12.1 | 10.6 ± 15.1 | 25.4 ± 10.6 | <0.05, | 10.9 ± 13.9 |
RML | 20.1 ± 16.5 | 25.6 ± 15.3 | 32.1 ± 19.1 | 0.187 | 19.9 ± 17.7 | |
RLL | 3.8 ± 8.6 | 6.9 ± 8.9 | 11.1 ± 10.0 | <0.01, | 3.9 ± 7.2 | |
LUL | 11.9 ± 14.3 | 12.6 ± 12.6 | 23.0 ± 9.2 | 0.086 | 12.1 ± 14.9 | |
LLL | 4.6 ± 9.6 | 8.6 ± 11.2 | 9.6 ± 6.6 | <0.05 | 3.3 ± 6.2 | |
Total | 8.7 ± 10.5 | 11.1 ± 11.8 | 18.2 ± 9.0 | 0.064 | 8.7 ± 10.5 |
Clinical characteristics | NN type (N = 38) | LA type (N = 18) | SA type (N = 5) | P value |
---|---|---|---|---|
Asthma severity (Severe) | 14 (36.8%) | 14 (77.8%) | 5 (100%) | <0.005 |
Age (y) | 66.5 [57.0; 74.0] | 63.0 [56.0; 67.0] | 68.0 [53.0; 76.0] | 0.574 |
Onset age of asthma (y) | 53.0 [42.0; 62.0] | 46.5 [40.0; 56.0] | 54.0 [44.0; 59.0] | 0.548 |
Disease duration (y) | 11.0 [9.0; 17.0] | 15.0 [13.0; 23.0] | 14.0 [14.0; 17.0] | 0.324 |
Sex (female) | 29 (76.3%) | 11 (61.1%) | 0 (0%) | <0.005 |
Smoking status (Never/Former/Current) | 32/6/0 (84.2/15.8/0%) | 12/5/1 (66.7/27.8/5.6%) | 0/3/2 (0/60/40%) | <0.001 |
BMI (kg/m2) | 24.6 ± 3.1 | 24.4 ± 1.9 | 23.3 ± 2.4 | 0.794 |
Sinusitis | 22 (57.9%) | 12 (66.7%) | 4 (80%) | 0.656 |
Nasal polyp | 4 (10.5%) | 4 (22.2%) | 0 (0%) | 0.323 |
Atopy | 12 (31.6%) | 5 (27.8%) | 1 (20%) | 1.000 |
Total IgE (IU/ml) | 62.0 [27.0; 145.0] | 94.0 [40.0; 469.0] | 42.0 [30.5; 886.5] | 0.491 |
Sputum eosinophil (%) | 3.3 [3.0; 5.0] | 9.3 [4.8; 17.7] | 7.7 [5.0; 10.2] | <0.05 |
Sputum neutrophil (%) | 1.0 [0.7; 3.7] | 1.2 [0.5; 2.5] | 3.0 [2.3; 5.7] | 0.263 |
FeNO (ppb) | 23.7 ± 14.2 | 28.9 ± 17.8 | 22.2 ± 13.9 | 0.372 |
PC20 (mg/ml, at diagnosis) | 9.3 [3.6; 16.8] | 5.3 [2.0; 13.3] | 1.4 [1.0; 1.4] | <0.05 |
Pre-BD FVC (%pred) | 81.3 ± 22.1 | 69.1 ± 10.5 | 72.8 ± 16.2 | <0.05 |
Pre-BD FEV1 (%pred) | 87.6 ± 21.0 | 62.7 ± 14.8 | 54.8 ± 10.3 | <0.001, |
Pre-BD FEV1/FVC (%) | 85.3 ± 7.8 | 74.9 ± 14.3 | 62.4 ± 3.9 | <0.001, |
Post-BD FVC (%pred) | 84.6 ± 17.9 | 75.0 ± 12.2 | 78.2 ± 21.4 | 0.15 |
Post-BD FEV1 (%pred) | 91.9 ± 21.2 | 69.1 ± 15.4 | 57.8 ± 10.9 | <0.001, |
Post-BD FEV1/FVC (%) | 87.0 ± 7.1 | 74.6 ± 14.5 | 61.8 ± 8.2 | <0.001, |
Fixed obstruction | 0 (0%) | 6 (33.3%) | 3 (60%) | <0.001, |
No. of controller medications | 1.5 ± 1.0 | 2.1 ± 1.1 | 2.2 ± 1.3 | <0.05 |
Maintenance of OCS (%) | 11 (28.9%) | 11 (61.1%) | 3 (60%) | <0.05 |
No. of acute exacerbations (per year, 2012–2017) | 0.1 [0.0; 0.3] | 0.4 [0.0; 0.7] | 0.7 [0.5; 1.0] | <0.05 |

Discussion
Abbreviations
Financial support
Authors’ contributions
Consent for publication
Availability of data and materials
Ethics approval
Declaration of competing interest
Acknowledgments
Appendix A. Supplementary data
- Multimedia component 1
- Supplemental Fig. S1
Flow chart of enrolled and excluded subjects.
- Supplemental Fig. S2
Representative images of each phenotype determined through CT: NN type (A), LA type (B), and SA type (C).
- Supplemental Fig. S3
Screen plot of eigenvalues according to the number of principal components (A), cluster stability analysis using bootstrapping (B), clustering membership of K-means clustering (C) and hierarchical clustering (D) on 2D projected coordinates.
References
- Structural changes in the airways in asthma: observations and consequences.Clin Sci (Lond). 2005; 108: 463-477
- Mechanisms of airway remodeling. Airway smooth muscle.Am J Respir Crit Care Med. 2001; 164: S63-S66
- Mechanisms of airway remodeling.Chest. 2013; 144: 1026-1032
- Asthma. N Engl J Med. 2001; 344: 350-362
- An official American thoracic society research statement: current challenges facing research and therapeutic advances in airway remodeling.Am J Respir Crit Care Med. 2017; 195: e4-e19
- Basic mechanisms of development of airway structural changes in asthma.Eur Respir J. 2007; 29: 379-389
- A multivariate analysis of risk factors for the air-trapping asthmatic phenotype as measured by quantitative CT analysis.Chest. 2009; 135: 48-56
- Improved CT-based estimate of pulmonary gas trapping accounting for scanner and lung volume variations in a multi-center study.J Appl Physiol. 2014; 117 (1985): 593-603
- Uncontrolled asthma phenotypes defined from parameters using quantitative CT analysis.Eur Radiol. 2019; 29: 2848-2858
- Airway remodeling measured by multidetector CT is increased in severe asthma and correlates with pathology.Chest. 2008; 134: 1183-1191
- Quantitative assessment of multiscale structural and functional alterations in asthmatic populations.J Appl Physiol. 2015; 118 (1985): 1286-1298
- Relationship between lung function and quantitative computed tomographic parameters of airway remodeling, air trapping, and emphysema in patients with asthma and chronic obstructive pulmonary disease: a single-center study.J Allergy Clin Immunol. 2016; 137: 1413-+
- Associations in asthma between quantitative computed tomography and bronchial biopsy-derived airway remodelling.Eur Respir J. 2017; 49
- Computed tomography scans in severe asthma: utility and clinical implications.Curr Opin Pulm Med. 2012; 18: 42-47
- Temporal assessment of airway remodeling in severe asthma using quantitative computed tomography.Am J Resp Crit Care. 2015; 191: 107-110
- Severe asthma phenotypes classified by site of airway involvement and remodeling via chest CT scan.J Investigat Allergol Clin Immunol. 2018; 28: 312-320
- International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma.Eur Respir J. 2014; 43: 343-373
- Mass preserving nonrigid registration of CT lung images using cubic B-spline.Med Phys. 2009; 36: 4213-4222
- Registration-based assessment of regional lung function via volumetric CT images of normal subjects vs. severe asthmatics.J Appl Physiol. 2013; 115 (1985): 730-742
- Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression.Nat Med. 2012; 18: 1711-1715
- fpc: Flexible Procedures for Clustering.2014 (R package version 2.1-9 ed)
- Balance diagnostics after propensity score matching.Ann Transl Med. 2019; 7: 16
- A Language and Environment for Statistical Computing.R Foundation for Statistical Computing, 2013
- Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program.Am J Respir Crit Care Med. 2010; 181: 315-323
- Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis.J Allergy Clin Immunol. 2014; 133: 1557-15563 e5
- Unsupervised phenotyping of Severe Asthma Research Program participants using expanded lung data.J Allergy Clin Immunol. 2014; 133: 1280-1288
- Identification of asthma clusters in two independent Korean adult asthma cohorts.Eur Respir J. 2013; 41: 1308-1314
- Quantitative computed tomographic imaging-based clustering differentiates asthmatic subgroups with distinctive clinical phenotypes.J Allergy Clin Immunol. 2017; 140 (e8): 690-700
- Quantitative computed tomography-derived clusters: redefining airway remodeling in asthmatic patients.J Allergy Clin Immunol. 2014; 133: 729-738 e18
- Quantitative analysis of high-resolution computed tomography scans in severe asthma subphenotypes.Thorax. 2010; 65: 775-781
- Imaging of the Airways: Functional and Radiologic Correlations.Lippincott Williams & Wilkins, 2005: 133-134
- The role of chest radiography and computed tomography in the diagnosis and management of asthma.Curr Opin Pulm Med. 2007; 13: 31-36
- American thoracic society/national heart, lung, and blood Institute asthma-chronic obstructive pulmonary disease overlap workshop report.Am J Respir Crit Care Med. 2017; 196: 375-381
- Asthma-COPD overlap 2015: now we are six.Thorax. 2015; 70: 683-691
- Asthma-COPD overlap syndrome: pathogenesis, clinical features, and therapeutic targets.BMJ. 2017; 358: j3772
- The overlap syndrome of asthma and COPD: what are its features and how important is it?.Thorax. 2009; 64: 728-735
- Asthma and COPD overlap syndrome (ACOS): a systematic review and meta analysis.PLoS One. 2015; 10e0136065
- Asthma, COPD and overlap syndrome: a longitudinal study in young European adults.Eur Respir J. 2015; 46: 671-679
- The effect of disease and respiration on airway shape in patients with moderate persistent asthma.PLoS One. 2017; 12e0182052
- Noninvasive imaging biomarker identifies small airway damage in severe chronic obstructive pulmonary disease.Am J Respir Crit Care Med. 2019; 200: 575-581
- Transcriptomic gene signatures associated with persistent airflow limitation in patients with severe asthma.Eur Respir J. 2017; 50
Article info
Publication history
Footnotes
☆Full list of author information is available at the end of the article
Identification
Copyright
User license
Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) |
Permitted
For non-commercial purposes:
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article (private use only, not for distribution)
- Reuse portions or extracts from the article in other works
Not Permitted
- Sell or re-use for commercial purposes
- Distribute translations or adaptations of the article
Elsevier's open access license policy